Ratings Roche Holding AG Deutsche Boerse AG

Equities

RHO

CH0012032113

Market Closed - Deutsche Boerse AG Other stock markets 16:41:39 28/06/2019 BST			5-day change	1st Jan Change
247.6 ^EUR	+0.81%		-.--%	-.--%

05-31	ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	ZD
05-31	Transcript : Roche Holding AG - Shareholder/Analyst Call

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
This company will be of major interest to investors in search of a high dividend stock.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The company's enterprise value to sales, at 3.28 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ROCHE HOLDING AG	-.--%	206B	-
ELI LILLY AND COMPANY	+40.73%	739B	C+
NOVO NORDISK A/S	+32.83%	598B	B
JOHNSON & JOHNSON	-6.30%	353B	C+
MERCK & CO., INC.	+15.15%	318B	B-
ABBVIE INC.	+4.05%	285B	C+
ASTRAZENECA PLC	+15.00%	240B	B+
AMGEN INC.	+6.17%	164B	C+
PFIZER, INC.	-0.45%	162B	C+
SANOFI	-.--%	122B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes